|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||51.45 - 52.45|
|52 Week Range||24.84 - 52.54|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Anyone researching Cardiovascular Systems, Inc. (NASDAQ:CSII) might want to consider the historical volatility of the...
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems Inc (CSII) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Continue reading...
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems touted Paulsen’s support for the medical device industry and involvement with federal healthcare and economic policy in an announcement Thursday.
Today we are going to look at Cardiovascular Systems, Inc. (NASDAQ:CSII) to see whether it might be an attractive...
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
HealthEquity (HQY) is set to acquire WageWorks in an all-cash deal of about $2 billion. The buyout is expected to help HealthEquity to expedite the market-wide transition to HSAs.
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
Some analysts have started to price in "insurance cuts," which means they are expecting the Fed to cut rates right before a downturn in order to save the economy.
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.